Truscreen eyes profits and possible capital raise
Cancer test company positive after $4.5m loss announcement.
Medical device maker Truscreen says it expects to “reach profitability” in the coming year after reporting a loss of $4.5 million for the year to March.
Sales of its proprietary cervical cancer screening device were $804,062 for the year, up from $585,388 a year earlier. Truscreen said most of
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Tim Hunter
Fri, 15 Jun 2018
Fri, 15 Jun 2018
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Truscreen eyes profits and possible capital raise
75385